Compare Cassava Sciences Inc (FLNA) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Thomson Reuters Corp — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Thomson Reuters Corp trades at $98.83 (market cap $41.16B). The key difference: Thomson Reuters Corp is far larger — about 774.6× Cassava Sciences Inc's market cap, and Thomson Reuters Corp pays a 2.74% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TRI | |
|---|---|---|
Market Cap | $53.14M | $41.16B |
Sector | Health | Industrials |
52-Week High | $4.64 | $211.14 |
52-Week Low | $1.09 | $76.55 |
Enterprise Value | -$33.43M | $43.12B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Thomson Reuters (TRI) trades at $100.30, up 9.33% in the past 24 hours, reflecting strong momentum. The stock shows a bullish technical signal with moving averages and ADX supporting upward trends, though RSI indicates potential overbought conditions. Fundamentally, the company maintains robust profitability with a 19.93% net income margin and has beaten earnings estimates in two of the last three quarters. Recent developments include a joint venture with KKR for its global print business and continued AI integration, signaling strategic growth initiatives.
The outlook for TRI is positive, driven by analyst consensus favoring a Buy rating with a $129.96 price target, implying significant upside. Key opportunities lie in AI adoption and partnership expansions, but risks include execution challenges in technology transitions and potential revenue volatility. Investors should weigh strong fundamentals against near-term overbought technicals and competitive pressures in the information services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
